The Implications of Cost-effectiveness Analysis of Medical TechnologyCongress of the United States, Office of Technology Assessment, 1980 - 219 pages |
From inside the book
Results 1-5 of 56
Page 4
... consideration of economic factors . In health planning deci- sions , for example , planners would be asked to consider not only whether a service is needed but also whether it is worth the cost . The terms CBA and CEA refer to formal ...
... consideration of economic factors . In health planning deci- sions , for example , planners would be asked to consider not only whether a service is needed but also whether it is worth the cost . The terms CBA and CEA refer to formal ...
Page 6
... considerations . Finally , CEA / CBA must often address issues of great uncertainty , such as disease progression , patient compliance rates , differing responses to tech- nology by differing population groups , and so on . These and ...
... considerations . Finally , CEA / CBA must often address issues of great uncertainty , such as disease progression , patient compliance rates , differing responses to tech- nology by differing population groups , and so on . These and ...
Page 7
... consideration . The findings of this assessment , especially methodological ones , focus primarily on the practical implications of CEA / CBA for health policy . The report is not written for the aca- demic research community . The ...
... consideration . The findings of this assessment , especially methodological ones , focus primarily on the practical implications of CEA / CBA for health policy . The report is not written for the aca- demic research community . The ...
Page 9
... consideration of how to get the most health effect for the fewest dollars . Market approval for drugs and medical de- vices , by the Food and Drug Administration ( FDA ) , is an area where Congress has specified the decision criteria ...
... consideration of how to get the most health effect for the fewest dollars . Market approval for drugs and medical de- vices , by the Food and Drug Administration ( FDA ) , is an area where Congress has specified the decision criteria ...
Page 10
United States. Congress. Office of Technology Assessment. POLICY OPTIONS Options for congressional consideration fall ... considerations , along with considerations of the country's limited experience with making health care allocation ...
United States. Congress. Office of Technology Assessment. POLICY OPTIONS Options for congressional consideration fall ... considerations , along with considerations of the country's limited experience with making health care allocation ...
Other editions - View all
Common terms and phrases
Administration advisory agencies application areas assessment Background Paper biomedical Blue Shield budget Cancer CEA and CBA CEA or CBA CEA/CBA clinical trials conducted considerations Cost of Illness Cost-Benefit Analysis cost-benefit studies cost-effectiveness costs and benefits coverage criteria deci decisionmaking DHHS disease economic economists effectiveness enrollees evaluation example FDA's Federal formal CEA/CBA funding goals gram HCFA Health Care Technology Health Maintenance Organizations health planning health services research hospital HSAs identified impact individual Institute issues measure medical devices medical technologies medicare ment methodological Mishan National NCHCT NCHSR nomic Office option organizations outcomes panel peer review performance physicians policymakers potential priority problem procedures PSRO Public Law quality-adjusted reimbursement safety and efficacy scientific sions social specific staff standards tech techniques tion tive treatment types U.S. Congress
Popular passages
Page 88 - As used in this subsection and subsection (e), the term "substantial evidence" means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is presented to have under the conditions of use prescribed, recommended,...
Page 48 - A), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA).
Page 88 - Administration with respect to such drug, there is lack of substantial evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested...
Page 62 - ... (B) the quality of such services meets professionally recognized standards of health care ; and (C) in case such services and items are proposed to be provided in a hospital or other health care facility on an inpatient basis, such services and items could, consistent with the provision of appropriate medical care, be effectively provided on an outpatient basis or more economically in an inpatient health care facility of a different type.
Page 191 - Risk: A measure of the probability of an adverse or untoward outcome and the severity of the resultant harm to health of individuals in a defined population associated with use of a medical technology applied for a given medical problem under specified conditions of use.
Page 47 - Notwithstanding any other provision of this title, no payment may be made under part A or part B for any expenses incurred for items or services — (/) which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member...
Page 52 - Nothing in this title shall be construed to authorize any Federal officer or employee to exercise any supervision or control over the practice of medicine or the manner in which medical services are provided...
Page 3 - Medical technology: The drugs, devices, and medical and surgical procedures used in medical care, and the organizational and supportive systems within which such care is provided.
Page 190 - Effectiveness: Same as efficacy (see below) except that it refers to average or actual conditions of use. Efficacy: The probability of benefit to individuals in a defined population from a medical technology applied for a given medical problem under ideal conditions of use.
Page 182 - First, cost-benefit analysis as generally understood is only a technique for taking decisions within a framework which has to be decided upon in advance and which involves a wide range of considerations, many of them of a political or social character.